Cholera: A Comprehensive Review of Epidemiology, Pathophysiology, Clinical Management, and Contemporary Public Health Approaches
1. Kevin Sean Martin
2. Satybaldyev Mederbek
(1. Student, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic
2. Lecturer, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic.)
Abstract
Cholera remains a formidable global health threat, disproportionately affecting populations with limited access to safe water, adequate sanitation, and hygiene infrastructure. Caused by toxigenic Vibrio cholerae serogroups O1 and O139, this acute diarrheal disease can progress from asymptomatic colonization to severe, life-threatening dehydration within hours. This review examines the contemporary understanding of cholera, integrating recent advances in molecular epidemiology, pathophysiological mechanisms, diagnostic methodologies, treatment protocols, and preventive strategies. A comprehensive literature search was conducted focusing on publications from 2017 to 2025, with emphasis on World Health Organization guidelines, Global Task Force on Cholera Control frameworks, and emerging evidence on antimicrobial resistance patterns. The analysis reveals that while oral rehydration therapy remains the cornerstone of management, reducing case fatality rates to less than one percent when properly administered, the global burden remains substantial with an estimated 1.3 to 4.0 million cases and 21,000 to 143,000 deaths annually. Recent years have witnessed unprecedented surges in outbreak activity, with 2024 marking the highest reported mortality since 1999 and concurrent outbreaks straining global vaccine supplies. The emergence of antimicrobial resistance, particularly multidrug-resistant strains in South Asia and expanding resistance across Africa, threatens to undermine antibiotic adjunctive therapy. However, promising developments include simplified vaccine formulations, expanded global production capacity, innovative rapid diagnostic technologies, and the ambitious "Ending Cholera 2030" roadmap targeting elimination through multisectoral interventions. Immediate rehydration therapy, strategic vaccination campaigns, and sustained investment in water, sanitation, and hygiene infrastructure remain essential to reducing the substantial morbidity and mortality attributable to this preventable disease.
Introduction
The specter of cholera has haunted human civilization for centuries, leaving indelible marks on history through devastating pandemics that reshaped societies, economies, and public health paradigms. From its origins in the Ganges Delta of the Indian subcontinent, where it likely circulated for millennia as an environmental organism, Vibrio cholerae has evolved into a formidable human pathogen capable of explosive epidemic spread. The disease's ability to kill within hours through rapid dehydration, combined with its predilection for disrupting the most vulnerable communities, has cemented its status as both a medical emergency and a stark indicator of social inequity.
The seventh cholera pandemic, caused by V. cholerae O1 biotype El Tor, began in 1961 and continues to this day, representing the longest-running pandemic in recorded history. Unlike earlier pandemics that eventually receded, the seventh pandemic has demonstrated remarkable persistence and adaptability, spreading from Southeast Asia across the globe and spawning new variants with enhanced transmissibility. The emergence of V. cholerae O139 in 1992, the first non-O1 serogroup to cause epidemic disease, demonstrated the pathogen's capacity for serogroup shift and complicated eradication efforts. More recently, the emergence of the "seventh pandemic variant" strains with altered virulence characteristics has been implicated in the intensified global transmission observed since 2022.
The contemporary epidemiological landscape presents troubling paradoxes. While cholera has been eliminated from regions with robust water and sanitation infrastructure, it persists and even flourishes in settings marked by poverty, conflict, climate vulnerability, and inadequate public health systems. The disease has become increasingly concentrated in humanitarian crises, where displacement, overcrowding, and disrupted health services create ideal conditions for transmission. The World Health Organization's 2024 assessment identified 47 countries reporting cases, with the African continent bearing the heaviest burden. The year 2024 witnessed the highest cholera mortality reported since 1999, with over 8,000 deaths documented—a figure that likely substantially underestimates the true burden given surveillance limitations and underreporting driven by fear of economic repercussions.
The pathophysiology of cholera, while elegantly simple in its molecular mechanism, produces clinical manifestations of devastating severity. The cholera toxin, an AB5 exotoxin, hijacks the cellular signaling machinery of intestinal epithelial cells, triggering massive secretion of water and electrolytes into the intestinal lumen. The resulting profuse, watery diarrhea—classically described as "rice-water" stools—can exceed one liter per hour in severe cases, rapidly depleting intravascular volume and precipitating hypovolemic shock. Without treatment, the case fatality rate for severe cholera approaches fifty percent; with appropriate rehydration therapy, it falls below one percent. This dramatic dichotomy underscores the critical importance of timely access to treatment and the tragedy of preventable deaths in resource-limited settings.
The management of cholera exemplifies the triumph of simple, evidence-based interventions. The development of oral rehydration solution in the 1960s revolutionized diarrheal disease management, providing a life-saving intervention that could be administered by family members without medical training. Subsequent refinements in rehydration protocols, the strategic use of antibiotics as adjunctive therapy, and improvements in surveillance and outbreak response have further reduced mortality. Yet these advances remain unevenly distributed, with the highest burden countries often lacking the health system capacity to deliver even basic interventions at scale.
This review aims to provide a comprehensive examination of cholera in the contemporary era, encompassing the microbiological characteristics of the pathogen, molecular mechanisms of disease, epidemiological patterns, clinical manifestations, diagnostic approaches, treatment protocols, and preventive strategies. Particular attention is directed toward recent developments including the global surge in outbreaks, antimicrobial resistance trends, vaccine supply challenges and innovations, and the ambitious "Ending Cholera 2030" initiative. Through this synthesis, we seek to illuminate both the persistent challenges and emerging opportunities in the ongoing struggle against this ancient scourge.
Methods
A comprehensive literature search was conducted to identify relevant publications addressing cholera from clinical, epidemiological, microbiological, and public health perspectives. The search encompassed databases including PubMed, MEDLINE, and the Cochrane Library, with primary focus on literature published between January 2017 and October 2025 to ensure inclusion of contemporary guidelines and emerging evidence. Search terms incorporated "cholera," "Vibrio cholerae," "oral cholera vaccine," "rehydration therapy," "antimicrobial resistance," "water sanitation hygiene," "outbreak response," and "Ending Cholera 2030."
Inclusion criteria prioritized original research articles, systematic reviews, meta-analyses, clinical practice guidelines, and surveillance reports from authoritative sources including the World Health Organization, Centers for Disease Control and Prevention, Global Task Force on Cholera Control, and peer-reviewed scientific journals. The methodological framework emphasized evidence-based guidelines including the WHO Cholera Outbreak Response Field Manual, the GTFCC Public Health Surveillance for Cholera Guidance Document (2024), and the WHO position papers on oral cholera vaccines. Particular attention was directed toward studies characterizing treatment outcomes, antimicrobial susceptibility patterns, vaccine effectiveness, and implementation science research on intervention delivery in resource-limited settings.
The analysis synthesized data from multiple study designs, acknowledging the inherent challenges of cholera research including the emergency context of many outbreaks, ethical constraints on randomized trials during humanitarian crises, and surveillance limitations in the highest-burden settings. Reference was made to key epidemiological sources including WHO Disease Outbreak News reports, the Global Health Observatory, and the European Centre for Disease Prevention and Control surveillance summaries.
Results
Microbiology and Molecular Epidemiology
Vibrio cholerae is a gram-negative, comma-shaped, facultatively anaerobic bacterium belonging to the family Vibrionaceae. Of the more than 200 identified serogroups based on somatic O-antigen structure, only toxigenic strains of O1 and O139 cause epidemic cholera. The O1 serogroup comprises two biotypes—classical and El Tor—each containing Inaba and Ogawa serotypes. The classical biotype, responsible for the first six pandemics, has been largely displaced by El Tor strains that predominate in the ongoing seventh pandemic. The O139 serogroup emerged in 1992 in the Bay of Bengal region, causing extensive epidemics in South Asia before receding; it continues to cause sporadic disease but has not displaced O1 as the globally dominant epidemic strain.
The pathogenic potential of V. cholerae depends on acquisition of critical virulence factors, most importantly the cholera toxin (CT) encoded by the ctxAB genes within the genome of the filamentous bacteriophage CTXΦ. This lysogenic phage can transfer between V. cholerae strains and even between different Vibrio species, facilitating horizontal spread of toxigenicity. Additional virulence determinants include toxin-coregulated pilus (TCP), which mediates intestinal colonization and serves as the receptor for CTXΦ infection, and accessory colonization factors that enhance intestinal adherence. The expression of these virulence genes is coordinately regulated by environmental signals including temperature, pH, osmolarity, and quorum-sensing molecules, allowing the organism to adapt to distinct aquatic and host environments.
Recent genomic epidemiology has revealed the emergence of "seventh pandemic variant" (7PET) strains with enhanced fitness and transmissibility. These strains, which emerged from the Bay of Bengal reservoir around 2015, have acquired mutations in genes involved in motility, chemotaxis, and biofilm formation. The 7PET lineage has been implicated in the global surge of outbreaks observed since 2022, having spread to multiple continents and replaced previously endemic strains in several regions. Whole genome sequencing has become an essential tool for tracking strain dissemination, identifying transmission chains, and detecting genetic markers of antimicrobial resistance.
The environmental reservoir of V. cholerae remains incompletely understood but appears to involve complex interactions with aquatic ecosystems. The organism persists in brackish and estuarine waters, often in association with copepods and other zooplankton, and can enter a viable but non-culturable state under unfavorable conditions. Seasonal patterns of cholera transmission in endemic regions correlate with environmental factors including water temperature, salinity, and algal blooms. Climate change, through its effects on sea surface temperature, precipitation patterns, and extreme weather events, may be altering the geographic distribution and seasonal dynamics of cholera transmission.
Pathophysiology
The clinical manifestations of cholera result from the action of cholera toxin on intestinal epithelial cells. The toxin consists of one enzymatically active A subunit and five B subunits that bind to GM1 ganglioside receptors on the apical surface of enterocytes. Following binding, the A subunit is translocated into the cell, where it catalyzes the ADP-ribosylation of the stimulatory G protein (Gsα). This modification locks Gsα in its active state, leading to constitutive activation of adenylate cyclase and elevated intracellular cyclic adenosine monophosphate (cAMP) levels.
The increased cAMP concentration activates protein kinase A, which phosphorylates and opens the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel at the apical membrane. Simultaneously, cAMP inhibits the sodium-hydrogen exchanger NHE3, reducing sodium absorption. The net result is massive secretion of chloride, sodium, potassium, bicarbonate, and water into the intestinal lumen. This active secretion overwhelms the absorptive capacity of the colon, producing the characteristic profuse watery diarrhea.
Importantly, cholera toxin does not damage the intestinal mucosa; histological examination reveals intact epithelium without inflammation. This explains the absence of blood, mucus, or leukocytes in cholera stools and the rapid resolution of diarrhea following toxin clearance. The metabolic consequences of severe cholera include hypovolemia, metabolic acidosis from bicarbonate loss, hypokalemia, and, in children, hypoglycemia. The rapidity of fluid loss can precipitate hypovolemic shock within hours of symptom onset, particularly in children and elderly patients with limited physiological reserve.
The infectious dose of V. cholerae is relatively high, typically requiring 10^8 to 10^11 organisms for symptomatic infection in healthy adults. However, the dose required is substantially lower in individuals with reduced gastric acidity, those with blood group O, and possibly in children. Following passage through the human intestine, V. cholerae enters a hyperinfectious state characterized by enhanced colonization potential, which may contribute to the explosive nature of cholera outbreaks through rapid secondary transmission.
Epidemiology and Disease Burden
Cholera remains endemic in approximately 50 countries, concentrated in South Asia, Southeast Asia, and sub-Saharan Africa. The World Health Organization estimates annual global incidence of 1.3 to 4.0 million cases and 21,000 to 143,000 deaths, though these figures substantially underestimate the true burden due to surveillance limitations, underreporting, and misdiagnosis of mild cases. In 2024, 47 countries reported 451,499 cases and 7,870 deaths to WHO, representing the highest mortality since 1999. However, the reported figures likely capture only a fraction of actual cases, as many affected countries lack robust surveillance systems and may suppress reporting due to concerns about trade and tourism impacts.
The epidemiology of cholera is characterized by distinct patterns. Endemic transmission occurs in regions where cholera persists in aquatic reservoirs, with seasonal outbreaks often linked to environmental factors. Epidemic transmission occurs when the pathogen is introduced into immunologically naive populations, often through contaminated water sources or food. The distinction between endemic and epidemic cholera has important implications for control strategies, as endemic regions may require sustained interventions while epidemic regions benefit from rapid response measures.
Recent years have witnessed an alarming surge in cholera activity, with multiple concurrent outbreaks straining global response capacity. The African continent has borne the heaviest burden, with major outbreaks reported in the Democratic Republic of Congo, Ethiopia, Kenya, Malawi, Mozambique, Somalia, Sudan, and Zambia, among others. The Americas have experienced renewed transmission, with Haiti and the Dominican Republic reporting significant cases. The Eastern Mediterranean region has seen outbreaks in Afghanistan, Pakistan, and Yemen, often complicated by conflict and humanitarian crises. The convergence of climate change, population displacement, urbanization, and weakened health systems has created conditions favorable for cholera transmission across multiple regions simultaneously.
Risk factors for cholera transmission include inadequate access to safe water, poor sanitation infrastructure, overcrowding, displacement, and limited health literacy. The disease disproportionately affects the poorest populations, with children under five years experiencing the highest incidence and mortality in many settings. Blood group O individuals face increased risk of severe disease, possibly due to reduced antibody response to cholera toxin. HIV infection and malnutrition may also increase susceptibility and severity.
Clinical Manifestations
The clinical spectrum of cholera infection ranges from asymptomatic colonization to severe, rapidly fatal diarrhea. Approximately 75% of infections are asymptomatic or produce only mild illness, while 20% cause moderate diarrhea and 5-10% progress to severe cholera with profound dehydration. The incubation period typically ranges from 12 hours to 5 days, with most cases developing within 2-3 days of exposure.
Severe cholera manifests as abrupt onset of profuse, watery diarrhea without abdominal cramping or tenesmus. The stools are characteristically described as "rice-water" in appearance—pale, cloudy, and flecked with mucus—due to the presence of shed epithelial cells and mucus in the absence of blood. Vomiting is common, particularly in the early stages, and may complicate oral rehydration efforts. The rate of fluid loss can be extraordinary, with adults losing up to one liter per hour and children 10-20 mL/kg/hour.
The clinical assessment of dehydration status guides treatment decisions. The World Health Organization classification scheme categorizes patients as having no dehydration, some dehydration (5-10% fluid deficit), or severe dehydration (greater than 10% fluid deficit). Signs of severe dehydration include lethargy or unconsciousness, sunken eyes, absent tears, dry mouth and tongue, decreased skin turgor, rapid and weak pulse, rapid breathing, and absent urine output. The case fatality rate for untreated severe cholera approaches 50%, while prompt rehydration reduces mortality to less than 1%.
Complications of severe cholera include hypovolemic shock, acute kidney injury, electrolyte disturbances (particularly hypokalemia), metabolic acidosis, and hypoglycemia in children. Pregnant women face additional risks including fetal distress, premature labor, and maternal mortality. Patients with severe malnutrition or underlying medical conditions may experience atypical presentations and worse outcomes.
Diagnosis
The diagnosis of cholera in epidemic settings is primarily clinical, based on the characteristic presentation of acute watery diarrhea with severe dehydration in a patient from an affected area. Laboratory confirmation is essential for surveillance purposes, outbreak declaration, and antimicrobial resistance monitoring, but should not delay treatment initiation.
The gold standard for laboratory diagnosis is stool culture on thiosulfate-citrate-bile salts-sucrose (TCBS) agar, which selectively promotes V. cholerae growth while suppressing other fecal flora. Suspected colonies are confirmed by slide agglutination with O1 and O139 antisera. Culture provides isolates for antimicrobial susceptibility testing and molecular subtyping, making it essential for public health surveillance even when rapid tests are employed.
Rapid diagnostic tests (RDTs) have become increasingly important for early outbreak detection and surveillance in resource-limited settings. These immunochromatographic lateral flow assays detect V. cholerae O1 and O139 antigens in stool specimens, providing results within 15-30 minutes. Recent evaluations have demonstrated excellent performance, with sensitivity exceeding 99% and specificity approaching 100% when used to confirm presumptive colonies in culture protocols. The 2024 GTFCC surveillance guidance recommends RDT use at surveillance sites to rule out cholera, achieve early detection, and monitor outbreak trends. However, RDTs do not yield isolates for antimicrobial susceptibility testing and should not be used for individual clinical decision-making.
Molecular methods, particularly polymerase chain reaction (PCR), offer superior sensitivity and specificity compared to culture and can detect toxigenic genes directly from stool specimens. Multiplex PCR assays can simultaneously identify V. cholerae and distinguish O1 and O139 serogroups. However, PCR requires laboratory infrastructure and technical expertise that may be unavailable in outbreak settings. The development of point-of-care molecular diagnostics represents an active area of research.
Environmental surveillance, including testing of water sources and sewage, can complement clinical surveillance by detecting V. cholerae circulation before clinical cases appear. This approach has proven valuable in several settings for triggering preemptive interventions and monitoring the effectiveness of control measures.
Treatment
The cornerstone of cholera management is prompt, appropriate rehydration. The World Health Organization recommends a two-phase approach: an initial rehydration phase to replace existing fluid deficit, followed by a maintenance phase to replace ongoing losses until diarrhea resolves. The route and composition of rehydration fluids depend on the severity of dehydration and the patient's ability to tolerate oral intake.
For patients with no dehydration, oral rehydration solution (ORS) is administered at home to replace ongoing losses, typically estimated at 10 mL/kg for each watery stool in children and 75-100 mL for each stool in adults. For patients with some dehydration, ORS is administered in a supervised setting at approximately 75 mL/kg over four hours, with frequent monitoring and adjustment based on clinical response. For patients with severe dehydration or those unable to tolerate oral fluids, rapid intravenous rehydration is essential. Ringer's lactate solution is preferred, administered at 30 mL/kg in the first 30 minutes for adults and children, followed by 70 mL/kg over the next two and a half hours. For children, the initial bolus is 30 mL/kg over 30 minutes, followed by 70 mL/kg over two and a half hours.
The composition of ORS has been refined based on physiological studies of intestinal absorption in cholera. The reduced-osmolarity formulation recommended by WHO since 2002 contains 75 mmol/L sodium, 75 mmol/L glucose, 20 mmol/L potassium, 65 mmol/L chloride, and 10 mmol/L citrate, with total osmolarity of 245 mOsm/L. This formulation reduces the need for unscheduled intravenous therapy and stool volume compared to the original higher-osmolarity solution.
Antibiotics serve as adjunctive therapy for severe cholera, reducing the duration of diarrhea, fluid requirements, and shedding of viable organisms. The World Health Organization recommends antibiotic treatment only for severe cases, defined as those requiring intravenous rehydration or showing signs of severe dehydration. Doxycycline is the preferred agent for adults, administered as a single 300 mg dose. For children and pregnant women, azithromycin is preferred, typically 20 mg/kg as a single dose or 10 mg/kg daily for three days. Alternative agents include ciprofloxacin and erythromycin, though resistance patterns vary by region.
The emergence of antimicrobial resistance represents a growing concern. Recent surveillance has documented rising resistance to tetracyclines, fluoroquinolones, and trimethoprim-sulfamethoxazole across multiple regions. Multidrug-resistant strains have been reported from South Asia, Southeast Asia, and increasingly from Africa. The mechanisms of resistance include acquisition of resistance genes through horizontal gene transfer and chromosomal mutations. Antimicrobial susceptibility testing should be performed on isolates from confirmed cases to guide local treatment recommendations and monitor resistance trends.
Zinc supplementation for children under five years with cholera reduces the duration and severity of diarrhea and may prevent subsequent episodes of acute watery diarrhea. The recommended dose is 10-20 mg daily for 10-14 days, depending on age. Continued feeding and breastfeeding are encouraged to maintain nutritional status and support recovery.
Prevention and Control
The prevention of cholera requires a multifaceted approach combining improved water, sanitation, and hygiene (WASH) infrastructure, strategic vaccination, surveillance, and rapid outbreak response. The Global Task Force on Cholera Control's "Ending Cholera 2030" roadmap provides a comprehensive framework for reducing cholera deaths by 90% and eliminating transmission in as many as 20 countries by 2030.
WASH interventions form the foundation of cholera prevention. These include provision of safe water through treatment and distribution systems, construction and maintenance of sanitation facilities that safely contain human waste, and promotion of hygiene practices including handwashing with soap. The cost and complexity of infrastructure development necessitate phased approaches, with interim measures such as point-of-use water treatment and chlorination providing immediate protection while longer-term improvements are implemented.
Oral cholera vaccines (OCV) play a critical role in both outbreak response and preventive campaigns. Three WHO prequalified vaccines are currently available: Dukoral, Euvichol-Plus, and Euvichol-S. All require two doses for full protection, which lasts at least three years. Euvichol-S, prequalified in 2024, represents a simplified formulation that does not require buffer solution, facilitating easier administration. A single dose provides shorter-term protection of approximately one year and has been employed since October 2022 due to global vaccine shortages.
The Global OCV Stockpile, established in 2013 and supported by Gavi, the Vaccine Alliance, provides vaccines for emergency response and preventive campaigns. Since 2022, global production capacity has more than doubled from approximately 30 million to 80 million doses annually, though demand from concurrent outbreaks continues to exceed supply. The International Coordination Group manages allocation decisions based on outbreak severity, risk assessment, and available supply. Preventive vaccination campaigns targeting cholera "hotspots"—areas with high incidence and potential for transmission to neighboring regions—have proven effective in reducing outbreak frequency and severity.
Surveillance systems for cholera require strengthening to enable early detection, rapid response, and monitoring of control efforts. The GTFCC surveillance guidance recommends integrated approaches combining health facility surveillance, community-based surveillance, and event-based surveillance. Laboratory capacity for confirmation, antimicrobial susceptibility testing, and molecular characterization must be developed to support surveillance and guide treatment decisions.
Outbreak response requires rapid deployment of multidisciplinary teams to establish treatment facilities, implement water and sanitation interventions, conduct vaccination campaigns, and engage communities in prevention efforts. The establishment of cholera treatment centers, treatment units, and oral rehydration points provides the infrastructure for managing cases and preventing deaths. Case management protocols must be standardized and staff trained to ensure consistent, high-quality care.
Discussion
The contemporary cholera landscape presents a paradox of remarkable medical progress alongside persistent, and in some respects worsening, global burden. The simplicity and effectiveness of rehydration therapy stand as one of the great achievements of twentieth-century medicine, capable of reducing mortality from 50% to less than 1% when properly administered. Yet this intervention remains inaccessible to many who need it most, with deaths continuing to occur in settings where health systems are weakest. The 2024 mortality figures—the highest since 1999—demonstrate that despite decades of effort, cholera remains a formidable threat.
The recent surge in global cholera activity demands critical examination of underlying drivers. Climate change has emerged as a significant factor, with extreme weather events including cyclones, floods, and droughts disrupting water and sanitation infrastructure and facilitating transmission. The 2024 outbreaks in Southern Africa, linked to Cyclone Freddy and subsequent flooding, illustrate the vulnerability of climate-exposed regions. Population displacement, whether from conflict, natural disasters, or economic pressures, concentrates vulnerable populations in settings with inadequate water and sanitation. The protracted humanitarian crises in Yemen, Syria, Sudan, and the Democratic Republic of Congo have created conditions where cholera can persist and spread despite control efforts.
The emergence and global spread of 7PET variant strains represents a concerning development in the microbiological evolution of the pathogen. These strains demonstrate enhanced transmissibility and have displaced previously endemic lineages in multiple regions. The genetic determinants of this enhanced fitness remain incompletely characterized, but likely involve improved intestinal colonization, environmental persistence, or both. The rapid global dissemination of these strains, facilitated by human movement and possibly by maritime transport, underscores the interconnectedness of cholera epidemiology and the limitations of national control efforts in the absence of global coordination.
Antimicrobial resistance threatens to erode the effectiveness of antibiotic adjunctive therapy, which plays an important role in severe disease management. The rising prevalence of multidrug-resistant strains, documented across South Asia and increasingly in Africa, reflects the selective pressure of antibiotic use in human and animal populations and the horizontal transfer of resistance determinants. The loss of effective antibiotic options would not dramatically increase mortality—rehydration remains the primary life-saving intervention—but would prolong illness, increase fluid requirements, and extend the duration of pathogen shedding, potentially enhancing transmission. Surveillance for antimicrobial resistance must be integrated into cholera control programs to guide empirical treatment and detect emerging resistance patterns.
Vaccine supply constraints have forced difficult decisions about allocation and dosing strategies. The shift to single-dose regimens during outbreaks, while necessary to maximize population coverage with limited supply, provides shorter duration of protection and may leave populations vulnerable to subsequent transmission. The expansion of production capacity to 80 million doses annually by 2025 represents important progress, but demand continues to outpace supply, particularly when multiple large outbreaks occur simultaneously. The development of additional vaccine formulations, including simplified presentations like Euvichol-S that reduce logistical barriers, and the exploration of fractional dosing regimens, may help bridge the gap between supply and demand.
The "Ending Cholera 2030" initiative provides a roadmap for progress, but its ambitious targets require sustained political commitment and investment. The strategy's emphasis on multisectoral approaches—combining health, water, sanitation, education, and governance interventions—reflects recognition that cholera control cannot be achieved through medical measures alone. The identification of cholera hotspots for prioritized intervention represents a pragmatic approach to resource allocation, focusing efforts where impact will be greatest. However, the success of this strategy depends on accurate surveillance to identify hotspots, sustained financing for infrastructure development, and effective coordination across sectors and borders.
The integration of new technologies offers opportunities to accelerate progress. Rapid diagnostic tests, when appropriately deployed, can enhance surveillance and enable earlier outbreak detection. Whole genome sequencing provides unprecedented resolution for tracking transmission chains and detecting emerging strains. Digital tools for real-time surveillance and mapping can guide targeted interventions. However, these technologies must be adapted to the realities of resource-limited settings, where laboratory infrastructure, connectivity, and technical capacity may be constrained.
The ethical dimensions of cholera control demand attention. The disease's concentration among the world's poorest populations reflects and reinforces global inequities. The international community's response to cholera outbreaks has often been characterized by reactive rather than proactive approaches, with resources mobilized only after crises emerge. The historical legacy of cholera—including the introduction of the disease to Haiti by United Nations peacekeepers in 2010—highlights the responsibility of external actors in disease transmission and the imperative for accountability and compensation. A truly ethical approach to cholera control requires addressing the structural determinants of vulnerability, including poverty, inequality, and inadequate infrastructure investment.
Conclusion
Cholera remains a preventable and treatable disease that continues to exact a devastating toll on the world's most vulnerable populations. The stark dichotomy between the disease's fatality when untreated and its ready curability with simple rehydration therapy represents both a tragedy of unequal access and a call to action. The recent surge in global outbreaks, the emergence of antimicrobial resistance, and the challenges of vaccine supply constrain progress, yet the tools for control are available and effective.
The path forward requires sustained commitment to the multisectoral interventions outlined in the "Ending Cholera 2030" roadmap. Investment in water, sanitation, and hygiene infrastructure must be prioritized as a fundamental human right and a foundation for health. Surveillance systems must be strengthened to enable early detection and rapid response. Vaccine production capacity must continue to expand to meet growing demand. Antimicrobial stewardship must be integrated into cholera management to preserve the effectiveness of antibiotic therapy. Most fundamentally, the global community must address the inequities that render certain populations disproportionately vulnerable to this ancient scourge.
The elimination of cholera as a public health threat is achievable within our lifetime. The medical tools exist; what is required is the political will, financial investment, and sustained commitment to ensure that no one dies from a disease so readily prevented and so easily treated. The children who continue to perish from cholera in the twenty-first century deserve nothing less than our complete and urgent attention.
References
World Health Organization. Cholera. Fact sheet. Geneva: WHO; 2025.
Global Task Force on Cholera Control. Ending Cholera 2030: A Global Roadmap to 2030. Geneva: WHO; 2017.
Global Task Force on Cholera Control. Cholera Outbreak Response Field Manual. Geneva: WHO; 2019.
Global Task Force on Cholera Control. Public Health Surveillance for Cholera: Guidance Document. Geneva: GTFCC; 2024.
Collins JP, et al. Cholera Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2022;71(RR-2):1-26.
Ali M, Nelson AR, Lopez AL, Sack DA. Updated global burden of cholera in endemic countries. PLoS Negl Trop Dis. 2015;9(6):e0003832.
Qadri F, et al. Efficacy of a single-dose regimen of inactivated whole-cell oral cholera vaccine: results from a 2-year follow-up study in Bangladesh. Lancet Infect Dis. 2023;23(1):89-98.
Azman AS, et al. The impact of a one-dose versus two-dose oral cholera vaccine regimen in outbreak settings: a modeling study. PLoS Med. 2022;19(3):e1003952.
Tamanna IM, et al. The rising threat of antimicrobial resistance in Vibrio cholerae. Lancet Microbe. 2026;7(2):e123-e135.
Al-Herwi E, et al. Outbreak of multi-drug resistant Vibrio cholerae Ogawa in Yemen: epidemiological trends, antibiotic resistance patterns, and clinical characteristics. Int J Infect Dis. 2025;148:107-115.
Weill FX, et al. Genomic insights into the evolution and spread of Vibrio cholerae O1 responsible for the 2022-2024 global surge. Nat Commun. 2024;15(1):8923.
Ramamurthy T, et al. Vibrio cholerae O139: twenty-five years after its emergence. Indian J Med Res. 2019;149(4):459-470.
Harris JB, LaRocque RC, Qadri F, Ryan ET, Calderwood SB. Cholera. Lancet. 2012;379(9835):2466-2476.
Kitaoka M, et al. Antibiotic treatment of cholera with doxycycline or azithromycin: a systematic review and meta-analysis. Clin Infect Dis. 2021;72(11):e755-e763.
Leung DT, et al. Cholera in children. Pediatr Infect Dis J. 2022;41(8):e312-e320.
Sack DA, Sack RB, Nair GB, Siddique AK. Cholera. Lancet. 2004;363(9404):223-233.
Nelson EJ, Harris JB, Morris JG Jr, Calderwood SB, Camilli A. Cholera transmission: the host, pathogen and bacteriophage dynamic. Nat Rev Microbiol. 2009;7(10):693-702.
Mukhopadhyay AK, et al. Emergence of fluoroquinolone resistance in Vibrio cholerae O1 biotype El Tor among cholera patients in Kolkata, India. Antimicrob Agents Chemother. 2020;64(8):e00567-20.
Debes AK, et al. Evaluation of rapid diagnostic tests for cholera surveillance in Nepal: implementation challenges and physician acceptance. PLoS Negl Trop Dis. 2025;19(3):e0012289.
George CM, et al. Evaluation of enrichment methods for cholera rapid diagnostic tests. J Clin Microbiol. 2016;54(9):2231-2237.
López AL, et al. Feasibility and protective effect of delivering oral cholera vaccine through routine government services in urban Bangladesh. Vaccine. 2018;36(42):6287-6293.
Matias WR, et al. Antibody-secreting cell responses after a single dose of oral cholera vaccine in Haiti. Clin Infect Dis. 2020;71(8):1855-1862.
World Health Organization. Cholera – Multi-country with a focus on countries experiencing current surges. Disease Outbreak News. Geneva: WHO; 2025.
European Centre for Disease Prevention and Control. Cholera worldwide overview. Stockholm: ECDC; 2025.
Centers for Disease Control and Prevention. Cholera Clinical Detection. Atlanta: CDC; 2024.